Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
44
BTAI Quote, Financials, Valuation and Earnings
Last price:
$2.01
Seasonality move
:
10.93%
Day range:
$1.92 - $2.03
52-week range:
$1.17 - $8.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.99x
P/B ratio:
--
Volume:
507.3K
Avg. volume:
554.3K
1-year change:
-67.41%
Market cap:
$44M
Revenue:
$2.3M
EPS (TTM):
-$9.70
Analysts' Opinion
-
Consensus RatingBioXcel Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.75, BioXcel Therapeutics, Inc. has an estimated upside of 733.33% from its current price of $2.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $2.01.
Fair Value
-
According to the consensus of 3 analysts, BioXcel Therapeutics, Inc. has 733.33% upside to fair value with a price target of $16.75 per share.
BTAI vs. S&P 500
-
Over the past 5 trading days, BioXcel Therapeutics, Inc. has overperformed the S&P 500 by 16.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioXcel Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioXcel Therapeutics, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter BioXcel Therapeutics, Inc. reported revenues of $98K.
Earnings Growth
-
BioXcel Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter BioXcel Therapeutics, Inc. reported earnings per share of -$2.18.
Enterprise value:
115.9M
EV / Invested capital:
--
Price / LTM sales:
19.99x
EV / EBIT:
--
EV / Revenue:
154.15x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-1.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$515K
Return On Assets:
-173.67%
Net Income Margin (TTM):
-9070.61%
Return On Equity:
--
Return On Invested Capital:
-512.4%
Operating Margin:
-14212.25%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2M | $2.3M | $752K | $214K | $98K | |
| Gross Profit | $293K | -$60K | -$515K | -$1M | $12K | |
| Operating Income | -$199.2M | -$73.1M | -$49.6M | -$13.4M | -$13.9M | |
| EBITDA | -$198.8M | -$72.8M | -$49.3M | -$13.3M | -$13.9M | |
| Diluted EPS | -$7.36 | -$2.15 | -$9.70 | -$0.32 | -$2.18 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $256.9M | $241.7M | $98.7M | $47.8M | $44.4M | |
| Total Assets | $261.3M | $244.8M | $100.4M | $48.9M | $44.8M | |
| Current Liabilities | $14.6M | $23.4M | $39.4M | $25.6M | $37.8M | |
| Total Liabilities | $15.8M | $117.8M | $141.1M | $134.5M | $133.7M | |
| Total Equity | $245.6M | $127M | -$40.6M | -$85.6M | -$88.9M | |
| Total Debt | $1.2M | $92.6M | $99.6M | $104.6M | $109.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$166.8M | -$84.1M | -$58.2M | -$16.3M | -$18.8M | |
| Cash From Investing | -$20K | -- | -- | -- | -- | |
| Cash From Financing | $24.4M | $34.5M | $55.1M | $454K | $37.5M | |
| Free Cash Flow | -$166.8M | -$84.1M | -$58.2M | -$16.3M | -$18.8M | |
BTAI
Sector
Market Cap
$44M
$28.1M
Price % of 52-Week High
24.88%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-114.95%
-1.59%
1-Year Price Total Return
-67.41%
-17.31%
Beta (5-Year)
0.213
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.78
200-day SMA
Sell
Level
$2.29
Bollinger Bands (100)
Sell
Level
1.6 - 3.6
Chaikin Money Flow
Sell
Level
-202.2M
20-day SMA
Buy
Level
$1.84
Relative Strength Index (RSI14)
Buy
Level
57.12
ADX Line
Buy
Level
16.72
Williams %R
Sell
Level
-17.7419
50-day SMA
Buy
Level
$1.90
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
654.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-28.5887)
Sell
CA Score
(Annual)
Level (-13.9844)
Sell
Beneish M-Score
(Annual)
Level (0.2182)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (23.519)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Stock Forecast FAQ
In the current month, BTAI has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BTAI average analyst price target in the past 3 months is $16.75.
-
Where Will BioXcel Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioXcel Therapeutics, Inc. share price will rise to $16.75 per share over the next 12 months.
-
What Do Analysts Say About BioXcel Therapeutics, Inc.?
Analysts are divided on their view about BioXcel Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioXcel Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is BioXcel Therapeutics, Inc.'s Price Target?
The price target for BioXcel Therapeutics, Inc. over the next 1-year time period is forecast to be $16.75 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BTAI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioXcel Therapeutics, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BTAI?
You can purchase shares of BioXcel Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioXcel Therapeutics, Inc. shares.
-
What Is The BioXcel Therapeutics, Inc. Share Price Today?
BioXcel Therapeutics, Inc. was last trading at $2.01 per share. This represents the most recent stock quote for BioXcel Therapeutics, Inc.. Yesterday, BioXcel Therapeutics, Inc. closed at $2.01 per share.
-
How To Buy BioXcel Therapeutics, Inc. Stock Online?
In order to purchase BioXcel Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BTAI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BTAI
Sector
P/E ratio
--
24.20x
PEG ratio
0.00x
-0.01x
P/B ratio
--
1.84x
Price / LTM sales
19.99x
1.60x
Growth Metrics
BTAI
Sector
Revenue growth
-54.21%
4.51%
Earnings growth
-576.21%
10.7%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.72
-$0.19
Profitability
BTAI
Sector
Profitability FY 2024
-$186K
$3.5M
Return on invested capital
-512.4%
-32.3%
Return on assets
-173.67%
-28.57%
Return on equity
--
-38.09%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
11
Balance Sheet
BTAI
Sector
Total cash
$37.3M
$26M
Short term investments
--
$25.7M
Total assets
$38.3M
$76.4M
Long term debt
$109.1M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
